2Chowdhry R, Marshall WL. Antifungal Therapies in the Intensive Care Unit [ J ]. Intensive Care Med,2008,23 ( 3 ) : 151 - 158.
3Chandrasekhar P. Management of invasive fungal infections:a role for polyenes [ J ]. Antimicrob Chemother, 2011,66 ( 3 ) :457 - 465.
4Limper AH. The Changing Spectrum of Fungal Infections In Pulmo- nary and Critical Care Practice:Clinical Approach To Diagnosis[ J]. Proceedings of the ATS, 2010,7 ( 3 ) : 163 - 168.
5Shoham S, Marwaha S. Invasive Fungal Infections in the ICU [ J ]. Intensive Care Med,2010,25 (3) :78 - 92.
6Dimopoulos G, Velegraki A, Falagas ME. A 10-Year Survey of Anti- fungal Susceptibility of Candidemia Isolates from Intensivd Care Unit Patients in Greece [ J ]. Antimicrob Agents Chemother, 2009,53 (3) :1242 - 1244.
7Bohme A, Ruhnke M, Buchheidt D, et al. Treatment of invasive fun- gal infections in cancer patients recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hema- tology and Oncology(DGHO) [ J] Ann Hematol,2009,88 ( 1 ) :97 -110.
8Limper AH, Knox KS, Sarosi GA, et al. An Official American Tho- racic Society Statement : Treatment of Fungal Infections in Adult Pul- monary and Critical Care Patients [ J]. Am J Respir Crit Care Med, 2011,183 ( 1 ) :96 - 128.
10Menzin J,Meyers JL,Friedman M. Mortality,length of hospitalization,and costs associated with invasive fungal infections in high-risk patients[J].American Journal of Health-System Pharmacy,2009,(19):1711-1717.
1Lockhart SR, Abramson MA, Beek- man SE, et al. Antimicrobial resistance among gram - negative bacilli as causes of infections in intensive care unit patients in the United States between 1993 and 2004 [J]. J Clin Microbiol, 2007,45(10) :3352 -3359.
2Karlsson S, Heikkinen M, Pettila V, et al. Predictive value of procalcitonin de- crease in patients with sever sepsis: a prospec- tive observational study [J]. Crit Care, 2010,14 (6) :205.
